Longitudinal determination of BNT162b2 vaccine induced strongly binding SARS-CoV-2 IgG antibodies in a cohort of Romanian healthcare workers. Issue 37 (2nd September 2022)

• Record Type: Journal Article
• Authors: Korodi, Mónika; Horváth, István; Rákosi, Kinga; Jenei, Zsuzsanna; Hudák, Gabriella; Kákes, Melinda; Dallos-Fejér, Katalin; Simai, Enikő; Páll, Orsolya; Staver, Natalia; Briciu, Violeta; Lupșe, Mihaela; Flonta, Mirela; Almaș, Ariana; Birlutiu, Victoria; Daniela Lupu, Claudia; Magdalena Ghibu, Andreea; Pianoschi, Dana; Terza, Livia-Maria; Fejer, Szilard N.
• Is Part Of: Vaccine. Volume 40:Issue 37(2022)
• Page Start: 5445
• Page End: 5451
• Publication Date: 2022-09-02
• Subjects: SARS-CoV-2 immune response -- Comirnaty -- Antibody waning -- Elisa assay -- IgG antibodies; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2022.07.040
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Mass vaccination against the disease caused by the novel coronavirus (COVID-19) was a crucial step in slowing the spread of SARS-CoV-2 in 2021. Even in the face of new variants, it still remains extremely important for reducing hospitalizations and COVID-19 deaths. In order to better understand the short- and long-term dynamics of humoral immune response, we present a longitudinal analysis of post-vaccination IgG levels in a cohort of 166 Romanian healthcare workers vaccinated with BNT162b2 with weekly follow-up until 35 days past the first dose and monthly follow-up up to 6 months post-vaccination. A subset of the patients continued with follow-up after 6 months and either received a booster dose or got infected during the Delta wave in Romania. Tests were carried out on 1694 samples using a CE-marked IgG ELISA assay developed in-house, containing S1 and N antigens of the wild type virus. Participants infected with SARS-CoV-2 before vaccination mount a quick immune response, reaching peak IgG levels two weeks after the first dose, while IgG levels of previously uninfected participants mount gradually, increasing abruptly after the second dose. Overall higher IgG levels are maintained for the previously infected group throughout the six month primary observation period (e.g. 36–65 days after the first dose, the median value in the previously infected group is 5.29 AU/ml, versus 3.58 AU/ml in the infection naïve group, p less than 0.001). The decrease of IgG levels is gradual, with lower median values in the infection naïve cohort even 7–8 months after vaccination, compared to the previously infected cohort (0.7 AU/ml versus 1.29 AU/ml, p = 0.006). Administration of a booster dose yielded higher median IgG antibody levels than post second dose in the infection naïve group and comparable levels in the previously infected group.